Substituted pyridinyl-pyrimidines and their use as medicaments

A compound of formula 1

• wherein
• ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O,
• wherein ring A may optionally be further substituted by one or two residues which are both independently from each other selected from the group consisting of H, halogen, C1-3-alkyl, -oxo, —NH2, —CO—(C1-3-alkyl), —CO—NH(C1-3-alkyl), —CO—N(C1-3-alkyl)2, —SO2-phenyl and —SO2—(C1-3-alkyl),
• and wherein
• R1 is selected from the group consisting of
• H, -halogen, SH, -oxo, —NH2, —CO—Y, —CO—N(CH3)—Y, —CO—N(CH3)—(C1-3-alkylene)-Y, —CS—Y, —CS—N(CH3)—Y, —CS—N(CH3)—(C1-3-alkylene)-Y, —C1-6-alkyl, —C1-3-haloalkyl, —CO—NH—Y, —CO—NH—C1-4-alkylene-Y, —CO—NH—C1-4-alkylene-(Y)2, —CO—N(CH3)—(C2-3-alkylene)-O—(C1-3-alkyl), —NH2, —C1-6-alkylene-L, —SO2-phenyl, —SO2—(C1-3-alkyl), —CO—N(C1-4-alkyl)2, —CO—N(C2-4-alkylene-O—C1-3-alkyl)2, a five- or six-membered heteroaromatic group comprising 1, 2 or 3 heteroatoms each independently selected from the group N, S and O,
• with Y being a group selected from the group consisting of —NH2, —NH(CH3), —N(CH3)2, —C1-6-alkylene-N(CH3)2, —O—C1-3-alkyl, —OH and —N(ethyl)2,
• or with Y being a group selected from the group consisting of a four-, five-, six- or seven-membered monocyclic fully saturated or partially unsaturated heterocycle comprising 1, 2 or 3 heteroatoms each independently selected from the group N, S and O, with the proviso that this heterocycle comprises at least one N-atom and that this heterocycle is directly attached to the molecule via this N-atom, a five- or six-membered monocyclic heteroaromatic group comprising 1, 2 or 3 heteroatoms each independently selected from the group of N, S and O, and a C3-6-cycloalkyl,
• or with Y being a 9- to 11-membered bicyclic annellated fully saturated or partially unsaturated heterocycle comprising 1, 2, 3 or 4 heteroatoms each independently from each other selected from the group N, S and O,
• or with Y being an 8- to 11-membered bicyclic fully saturated spiro-heterocycle comprising 1, 2 or 3 heteroatoms each independently selected from the group N, S and O, with the proviso that this spiro-heterocycle comprises at least one N-atom and that this heterocycle is directly attached to the molecule via this N-atom,
• or with Y being a six- or seven-membered fully saturated heterocycle comprising 1, 2 or 3 heteroatoms each independently selected from the group N, S and O, which is bridged by an additional C1-3-alkylene-unit,
• whereby each Y may optionally be substituted by one or more groups Z each independently from each other selected from the group consisting of halogen, -oxo, OH, C1-5-alkyl, —C1-5-alkanol, —O—C1-3-alkyl, a five-, six- or seven-membered fully saturated or partially unsaturated heterocycle comprising 1, 2 or 3 heteroatoms each independently selected from the group N, S and O;
• a fully saturated or partially unsaturated C3-6-cycloalkyl, a five- to six-membered heteroaromatic group comprising 1, 2 or 3 heteroatoms each independently selected from the group N, S and O;
• —CO-L, —C1-3-alkylene-CO-L, —C1-3-alkylene-O—C1-3-alkyl, —N(CH3)2 and —N(ethyl)2,
• whereby each group Z may optionally be further substituted by one, two or three groups T each independently selected from the group consisting of -oxo, OH, halogen, —C1-3-alkyl, —O—C1-3-alkyl, —N(methyl)2, —N(ethyl)2, 5- to 6-membered fully saturated, partially unsaturated or aromatic heterocycle comprising 1 or 2 heteroatoms each independently selected from the group N, O and S, a C3-6-cycloalkyl and —CN,
• wherein each group T may also optionally be substituted by a group selected from the group consisting of C1-3-alkyl, halogen, OH, oxo and —O—C1-3-alkyl,
• whereby L denotes a 5- or 6-membered fully saturated or partially unsaturated heterocycle comprising 1 or 2 heteroatoms each independently selected from the group N, O and S, which said heterocycle may optionally be substituted by one, two or three groups independently selected from among methyl, halogen, OH and -oxo,
• wherein R2 denotes a group selected from the group consisting of hydrogen, —OH, halogen, —CO—NH—NH2 and —CO—NH2,
• or R2 denotes a group selected from the group consisting of linear or branched C1-6-alkyl, —C1-6-haloalkyl, —R3, —O—R3, —O—C1-3-alkylene-R3, —C1-3-alkylene-O—C1-3-alkyl, linear or branched —O—C2-8-alkanol, linear or branched —O—C1-3-haloalkyl, —C3-6-cycloalkyl, —O—C2-4-alkylene-O—C1-3-alkyl, —CO—R3, —C1-4-alkylene-R3, —O—C2-6-alkenyl, —O—C2-4-alkylene-N(CH3)—C1-3-alkyl, —CO—N(C1-3-alkyl)2 and —CO—NH(C1-3-alkyl), which may optionally be substituted by one, two or three substituents each independently selected from the group consisting of —CN, —NH2, —C1-2-alkylene-CN, —OH, —C1-2-alkylene-OH, halogen, -oxo, —C1-3-alkyl, —O—R3, —C1-3-alkylene-O—R3, —CO—C1-6-alkyl, —CO—NH2, —CO—N(CH3)2, —C1-3-alkylene-NH2, phenyl, —C1-2-alkylene-OH and —CO—C1-2-alkyl,
• wherein each R3 denotes independently from each other a group selected from a linear or branched C1-10-alkyl, linear or branched C1-4-haloalkyl, fully saturated or partially unsaturated C3-8-cycloalkyl, —C1-3-alkylene-C3-6-cycloalkyl, a four-, five- or six-membered monocyclic either fully saturated or partially unsaturated heterocycle comprising 1, 2 or 3 heteroatoms each independently selected from N, S or O, a five- to six-membered heteroaromatic group comprising 1, 2 or 3 heteroatoms each independently selected from the group N, S and O, linear or branched —C2-5-alkenyl, phenyl and a nine- or ten-membered fully saturated, aromatic or partially unsaturated, bicyclic heterocycle comprising 1, 2 or 3 heteroatoms each independently selected from the group N, S and O
• wherein R4 denotes a group selected from H, F, Cl, Br, OH, —O—C1-3-alkyl, —C1-4-alkyl, —C1-3-alkylene-OH and —CN,
• wherein R5 denotes a group selected from H, F, Cl, Br, OH, —O—C1-3-alkyl, —C1-4-alkyl, —C1-3-alkylene-OH and —CN,
• wherein R6 denotes a group selected from H, halogen, C1-3-alkyl, —NH2, —C1-3-haloalkyl and —C1-4-alkoxy
• or a pharmaceutically acceptable salt thereof.